Pfizer Inc. PFE will release earnings for its third quarter before the opening bell on Tuesday, May 5. Analysts expect the ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

Pfizer will report Q1 2026 earnings on May 5, with analysts expecting revenue of about $13.8 billion, roughly matching last year’s level. The results will highlight progress in its pivot toward ...

The MarketWatch News Department was not involved in the creation of this content. -- Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals ...

The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes ...

Pfizer (PFE) reached $26.48 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.

Paying Patients to Access the Nation’s #1 Prescribed Oral Blood ThinnerPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #Eliquis--The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) — (Pfizer NYSE: PFE) Alliance ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...